News

Datroway reduced disease progression by 37% when compared with chemotherapy.

Here’s what you missed this week on Managed Healthcare Executive.

A forecast of the year by Bill Kerr, M.D., MBA, CEO of Avalon Healthcare Solutions.

Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund, explains the biggest HIV issues anticipated this year.

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.

This ranking is based on the reviews of 12,372 consumers who evaluated their experiences with 16 major health insurance brands.

Michael Poku, M.D., chief clinical officer of Equality Health, shared his prediction for 2025.

But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.

A prediction for 2025 from Laura Kohlhagen, M.D., MBA, chief medical officer, of Altera Digital Health.

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the intestinal tract, when compared to placebo.

Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.

Luke Twelves, M.D., vice president of Medical for Lindus Health, shared his prediction for the year.

Lyle Berkowitz, M.D., CEO of KeyCare, gives a prediction for 2025.

A prediction for 2025 by George Pappas, CEO of Intraprise Health.

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

UnitedHealth Group reported a medical care ratio in 2024 of 85.5% compared with 83.2% in 2023.

A prediction for the year by Brandi Meyers, vice president of Revenue Operations at MDClone.

A South Korean study explored the link between lifestyle decisions beginning in infancy and persistent atopic dermatitis, citing exclusive breast milk diet and childhood obesity as potential factors.

Kim Perry, chief growth officer of Emtelligent, shares her prediction for 2025.

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The FDA has set a goal date of Aug. 31, 2025.

Study authors Susan D. Reed, MD, MPH, MS, and Erin Dwyer, MPH, both at the University of Washington School of Medicine, attribute some of these different challenges to underlying health disparities.

A prediction of 2025 by Doug Mirsky, Ph.D., vice president of healthcare delivery at Digital Medicine Society.

A prediction for this year by Shawn Gremminger, president and CEO of National Alliance of Healthcare Purchaser Coalitions.

Jerilyn Arneson, Pharm. D, co-founder and officer of the National Association of Medication Access & Patient Advocacy, gives her 2025 prediction.

Centene Corporation’s Ambetter Health Solutions names Alan Silver as the first president of Individual Coverage Health Reimbursement Arrangements.

A forecast for 2025 by Guy D’Andrea, MBA, executive director of Catalyst for Payment Reform.

A prediction for 2025 by Marci Chodroff, M.D., vice president of Medical Affairs at Prime Therapeutics and Managed Healthcare Executive editorial advisory board member.

Kimberly Westrich, M.A., chief strategy officer of National Pharmaceutical Council, shares her prediction for 2025.